HomeCompareSCNLF vs MRK

SCNLF vs MRK: Dividend Comparison 2026

SCNLF yields 1373.63% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCNLF wins by $315919182.72M in total portfolio value
10 years
SCNLF
SCNLF
● Live price
1373.63%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$315919182.78M
Annual income
$276,344,297,604,930.75
Full SCNLF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SCNLF vs MRK

📍 SCNLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCNLFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCNLF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCNLF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCNLF
Annual income on $10K today (after 15% tax)
$116,758.24/yr
After 10yr DRIP, annual income (after tax)
$234,892,652,964,191.12/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SCNLF beats the other by $234,892,652,955,862.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCNLF + MRK for your $10,000?

SCNLF: 50%MRK: 50%
100% MRK50/50100% SCNLF
Portfolio after 10yr
$157959591.42M
Annual income
$138,172,148,807,364.44/yr
Blended yield
87.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SCNLF
No analyst data
Altman Z
-12.0
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCNLF buys
0
MRK buys
0
No recent congressional trades found for SCNLF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCNLFMRK
Forward yield1373.63%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$315919182.78M$56.8K
Annual income after 10y$276,344,297,604,930.75$9,798.13
Total dividends collected$313011682.66M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCNLF vs MRK ($10,000, DRIP)

YearSCNLF PortfolioSCNLF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$148,063$137,362.64$11,206$366.19+$136.9KSCNLF
2$2,059,200$1,900,773.30$12,650$502.35+$2.05MSCNLF
3$26,909,187$24,705,842.24$14,407$694.19+$26.89MSCNLF
4$330,522,388$301,729,558.78$16,585$967.82+$330.51MSCNLF
5$3,817,312,082$3,463,653,126.46$19,342$1,363.89+$3817.29MSCNLF
6$41,470,385,979$37,385,862,050.80$22,913$1,947.19+$41470.36MSCNLF
7$423,953,934,089$379,580,621,092.34$27,662$2,823.89+$423953.91MSCNLF
8$4,080,240,641,140$3,626,609,931,664.44$34,159$4,173.35+$4080240.61MSCNLF
9$36,985,873,996,458$32,620,016,510,437.74$43,337$6,308.80+$36985873.95MSCNLF
10$315,919,182,781,141$276,344,297,604,930.75$56,776$9,798.13+$315919182.72MSCNLF

SCNLF vs MRK: Complete Analysis 2026

SCNLFStock

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Full SCNLF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SCNLF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCNLF vs SCHDSCNLF vs JEPISCNLF vs OSCNLF vs KOSCNLF vs MAINSCNLF vs JNJSCNLF vs ABBVSCNLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.